Xi'an ruixi Biological Technology Co

Home > Keywords >

Catalog	name	Description	price
R-R-2276	Oclacitinib maleate CAS No.1640292-55-2	Oclacitinib maleate (PF-03394197 maleate)/CAS No.1640292-55-2 is a novel JAK inhibitor. Oclacitinib maleate (PF-03394197 maleate) is most potent at inhibiting JAK1 (IC50=10 nM).	price>
R-C-577	VU 0364439 cas:1246086-78-1	VU 0364439 is a positive allosteric modulator(PAM)of mGlu4 receptors(EC50=19.8 nM in vitro for human mGlu4).	price>
R-R-2277	Ruxolitinib (S enantiomer) CAS No.941685-37-6	Ruxolitinib (S enantiomer) (S-Ruxolitinib)/CAS No.941685-37-6 is the S-enantiomer of Ruxolitinib (HY-50856). Ruxolitinib (S enantiomer) is an orally active, potent JAK inhibitor.	price>
R-C-578	LY315920 cas:172732-68-2	LY315920(Varespladib)is a potent and selective secretory phospholipase A2 (sPLA) inhibitor with IC50 of 7 nM.In BAL cells challenged with human sPLA2,LY315920 at doses ranging from 0.1 μM–3μM reduces the formation of thromboxane mediated by human sPLA2 in a concentration-dependent manner with an IC50 of approximately 0.8 μM.	price>
R-R-2278	AZ960 CAS No.905586-69-8	AZ960/CAS No.905586-69-8 is a potent and specific inhibitor of the JAK2 kinase with a Ki of 0.45 nM.	price>
R-C-579	Anamorelin cas:249921-19-5	Anamorelin is currently under development for the management of non-small lung cancer associated cachexia/anorexia.	price>
R-R-2279	Brepocitinib P-Tosylate CAS No.2140301-96-6	Brepocitinib (PF-06700841) P-Tosylate/CAS No.2140301-96-6 is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC50s of 17 nM and 23 nM, respectively. Brepocitinib P-Tosylate also inhibits JAK2 and JAK3 with IC50s of 77 nM and 6.49 μM, respectively.	price>
R-C-580	Vistusertib (AZD2014) CAS:1009298-59-2	AZD2014 is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity.mTOR kinase inhibitor.	price>
R-R-2280	BMS-986202 CAS No.1771691-34-9	BMS-986202/CAS No.1771691-34-9 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC50 value of 0.19 nM and a Ki of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC50 value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium.	price>
R-C-581	LY2940680 cas:1258861-20-9	Taladegib(LY2940680)binds to the Smoothened(Smo)receptor and potently inhibits Hedgehog(Hh)signaling.	price>
R-R-2281	Izencitinib CAS No.2051918-33-1	Izencitinib (TD-1473)/CAS No.2051918-33-1 is an orally active, non-selective and gut-restricted JAK inhibitor. Izencitinib (TD-1473) can be used in the study for ulcerative colitis.	price>
R-C-582	LY500307 cas:533884-09-2	Erteberel(LY500307)is a potent and selective estrogen receptor beta(ERβ)agonist with Ki and EC50 of 1.54 nM and 3.61 nM,respectively.Anti-tumor activities.	price>
R-R-2282	Golidocitinib CAS No.2091134-68-6	AZD4205/CAS No.2091134-68-6 is a selective inhibitor of JAK1, with an IC50 of 73 nM, weakly inhibits JAK2 (IC50>14.7 μM), and shows little inhibition on JAK3 (IC50>30 μM).	price>
R-C-583	LY2608204 cas:1234703-40-2	LY2608204 is a potent used to treat type 2 diabetes.In a clinical trial,a study was performed to evaluate the safety and tolerability of LY2608204 in patients with type 2 diabetes.	price>
R-R-2283	Ilginatinib CAS No.1239358-86-1	Ilginatinib (NS-018)/CAS No.1239358-86-1 is a highly active and orally bioavailable JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM).	price>
R-C-584	TAK-700 (Orteronel) cas:566939-85-3	TAK-700(Orteronel) is a potent and highly selective human 17,20-lyase inhibitor with IC50 of 38 nM,exhibits >1000-fold selectivity over other CYPs (e.g.11-hydroxylase and CYP3A4).TAK-700(Orteronel) is an androgen biosynthesis inhibitor.	price>
R-R-2284	(Z)-LFM-A13 CAS No.244240-24-2	LFM-A13/CAS No.244240-24-2 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC50s of 2.5 μM, 10 μM and 61 μM; LFM-A13 shows no effects on JAK1 and JAK3, Src family kinase HCK, EGFR and IRK.	price>
R-C-585	Linagliptin(BI-1356) cas:668270-12-0	Linagliptin (BI-1356) is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM and exhibits a 10,000-fold higher selectivity for DPP-4 than for other dipeptidyl peptidases such as DPP-2, DPP-8,and DPP-9.Linagliptin activates glomerular autophagy in a model of type 2 diabetes.DPP4 mediates ferroptosis in TP53-deficient CRC cells.	price>
R-R-2285	Solcitinib CAS No.1206163-45-2	Solcitinib/CAS No.1206163-45-2 is an orally active, competitive, potent, selective JAK1 inhibitor, with an IC50 of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively; Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis.	price>
R-C-586	NVP-BHG712 cas:940310-85-0	NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf,c-Src and c-Abl with IC50 of 0.395 μM,1.266 μM and 1.667 μM,respectively.	price>

431432433434435436 437438439440441